Merck Research Labs Exec Joins VaxGen
This article was originally published in The Pink Sheet Daily
Former Merck Research Labs Executive Director-Microbial Vaccine Research Kathrin Jansen, PhD, has been named senior VP-R&D and chief scientific officer at VaxGen, the company announced Oct. 19
You may also be interested in...
FDA committee members express concern over vaccine's low CD8 cytotoxic T lymphocyte activity and lack of neutralizing antibody response in Phase II trial. Agency cites regulatory challenge associated with approving a vaccine that is not effective against U.S. sub-type of AIDS virus.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.